Omnicell®

Investor Relations

May 2, 2023



Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2023 guidance, strategic and growth opportunities, other expectations and other non-historical information. Without limiting the foregoing, statements including the words "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "believe," "forecast," "guidance," "outlook," "goals," "target," "estimate," "seek," "predict," "project," and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell's control and are subject to various risks and uncertainties, including those described below. Among other things, there can be no assurance that Omnicell's actual results will not differ, perhaps substantially, from the targets and expectations contained in this presentation.

Such statements also include, but are not limited to, Omnicell's projected bookings, revenues, including product, service, technical services and Advanced Services revenues, respectively, non-GAAP EBITDA, non-GAAP earnings per share, and estimated total addressable market; planned new products and services and the related expected benefits; and statements about Omnicell's strategy, objectives, and vision, including its corporate responsibility (innovation, environment, social and governance) goals and strategies. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) ability to realize the benefits of our expense containment efforts, (iii) Omnicell's ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iv) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (v) delays in installations of our medication management solutions or our more complex medication packaging systems, (vi) risks related to Omnicell's investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses, or technologies and successfully integrate such acquisitions, (vii) risks related to failing to maintain expected service levels when providing our Advanced Services or retaining our Advanced Services customers, (viii) Omnicell's ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ix) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (x) risks related to climate change, legal, regulatory or market measures to address climate change and related emphasis on ESG matters by various stakeholders, (xi) changes to the 340B Program, (xii) Omnicell's substantial debt, which could impair its financial flexibility and access to capital, (xiii) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity as a result of the previously disclosed ransomware incident, (xiv) any disruption in Omnicell's information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xv) risks associated with operating in foreign countries, (xvi) Omnicell's ability to recruit and retain skilled and motivated personnel, (xvii) Omnicell's ability to protect its intellectual property, (xviii) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xix) Omnicell's dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, and (xx) other risks and uncertainties further described in the "Risk Factors" section of Omnicell's most recent Annual Report on Form 10-K, as well as in Omnicell's other reports filed with or furnished to the United States Securities and Exchange Commission ("SEC"), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this presentation speak only as of the date of this presentation. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

Non-GAAP Financial Information

This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"), including 1Q 2023 non-GAAP gross margin, non-GAAP operating expense, non-GAAP EBITDA, and non-GAAP earnings per share, 2017 and 1Q2023 liquidity and 2017 and 1Q2023 net debt/EBITDA, guidance with respect to 2023 non-GAAP EBITDA and non-GAAP earnings per share. Reconciliations of the 2017 and 1Q2023 non-GAAP financial measures to the most directly comparable GAAP measures are included in the Appendix to this presentation. Our 2023 guidance for non-GAAP EBITDA and non-GAAP earnings per share, exclude certain items, which include, but are not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes. These excluded items may be significant. We do not provide a reconciliation of forward-looking non-GAAP guidance or targets to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. We believe such a reconciliation would imply a degree of precision that could be confusing or misleading to investors. These items may also have a material impact on GAAP earnings per share and GAAP net income in future periods. As such, these forward-looking non-GAAP financial measures are limited in their utility for evaluating our future operating results in accordance with GAAP.

OMNICELL, the Omnicell logo, and ENLIVENHEALTH are registered trademarks of Omnicell, Inc. or one its subsidiaries.

Our Mission

Be the clinician's most trusted partner for medication management.

We are dedicated to continuously deliver innovative technology that helps our customers improve patient care, *for everyone*.



Our Vision

Deliver the most compelling automation and services that accelerate pharmacy perfection.



© 2023 Omnicell, Inc.

Our Strategy

Fundamentally transform the pharmacy care delivery model by delivering a set of services that touch the entire continuum of care, built on a single cloud platform.



© 2023 Omnicell, Inc.

Omnicell: Compelling Growth Opportunities

1

Category creator transforming the pharmacy care delivery model

2

Leading strategic partner to health systems in large and growing market segments with $90 Billion+ Total Addressable Market (TAM)[1]

3

Resilient, long-term revenue growth accelerated by strong bookings, backlog and upgrade cycles

4

Demonstrated track record of growth built on a platform of intelligent infrastructure, spanning medication management across the continuum of care

Leveraging our market-leading installed base to drive recurring revenue growth in Advanced Services

© 2023 Omnicell, Inc.

1. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spain, Kingdom of Saudi Arabia and Australia/New Zealand.

1 The Autonomous Pharmacy Framework – an Industry Vision





© 2023 Omnicell, Inc.

1 Our Comprehensive Solutions Fundamentally Deliver Better Healthcare Value



© 2023 Omnicell, Inc.

2 Leader in Large and Growing Segments

Omnicell is growing its leadership position across a potential $90 Billion+ TAM

Estimated TAM Opportunity[1]



© 2023 Omnicell, Inc.

1. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spain, Kingdom of Saudi Arabia and Australia/New Zealand.

3 Revenue Growth Drivers

Deep Customer Relationships & Robust Backlog

- More than 150 of the top 300 U.S. health systems[1] in long-term sole-source agreements
- Robust backlog of $1.215 Billion as of 12/31/2022

Multiple Growth Drivers

- Customers increasingly turning to Omnicell for our platform-based approach to medication management
- Expansion opportunities within existing customer base
- Advanced Services expand our TAM
- Continued opportunities for competitive conversions

© 2023 Omnicell, Inc.
1. As of 03/31/23 and as defined by Definitive Healthcare.

3 Advanced Services Accelerating Recurring Revenue Growth

Advanced Services
(% of Total Revenue)

Targeting 18% of total revenue for 2023



- Leveraging established channels and strong customer relationships
- Strong demand driven by increasing provider digitization and need to evolve medication supply chain
- Omnicell's cloud-based services designed to enable better outcomes
- Subscription-based, recurring revenue streams
- Advanced Services expand our TAM

NOTE: Includes Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth solutions, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software solutions.

© 2023 Omnicell, Inc.

3 Advanced Services Business Model — Customer Example

Tech-Enabled Services Model (IVCS and CPDS)



End of year 7

Net sales type lease balance: $0

SaaS and Software Subscriptions Model



Transition to Advanced Services business model anticipated to provide: 1) Increased value to customers 2) Higher revenue versus previous model 3) Highly visible, recurring revenue & cash flow

© 2023 Omnicell, Inc.

4 Strong Balance Sheet

- Free cash flow projected to grow slower than EBITDA as Omnicell reinvests in the transformation to Advanced Services
- Liquidity and capital structure support growth strategy



1. Liquidity = Revolver Availability + Cash and Cash Equivalents; The amount of Revolver Availability is dependent on financial covenants.
2. Net Debt / EBITDA = (Total Debt - Cash and Cash Equivalents) / Trailing Twelve Month Non-GAAP EBITDA

DISCLAIMER: See Appendix for a reconciliation of 2017 and 1Q2023 Net Debt / EBITDA and 2017 and 1Q2023 Liquidity to their most directly comparable GAAP financial measures.

© 2023 Omnicell, Inc.

Backlog[1] ($Million)

By type:	As of December 31, 2022	As of December 31, 2021
Product Backlog	$797	$977
Advanced Services Backlog[2]	$418	$277
Total Backlog	**$1,215**	**$1,254**

By duration and type:	As of December 31, 2022	As of December 31, 2021
Short-Term Product Backlog	$503	$745
Long-Term Product Backlog	$294	$232
Short-Term Advanced Services Backlog[2]	$49	$37
Long-Term Advanced Services Backlog[2]	$369	$240
Total Backlog	**$1,215**	**$1,254**

1. Backlog is the dollar amount of bookings that have not yet been recognized as revenue. We consider backlog that is expected to be converted to revenues in more than twelve months to be long-term backlog. We believe a majority of long-term product backlog will be convertible into revenues in 12-24 months. Long-term Advanced Services backlog typically represents multi-year subscription agreements (usually with contractual terms of 2-7 years, some of which have not yet been implemented) that will be converted to revenue ratably over the contractual term.
2. Includes only the value of Advanced Services non-cancelable contracts with minimum commitments.

© 2023 Omnicell, Inc.

Total Year Revenue Composition

GAAP ($Million)	Recurring vs Non Recurring	Category	Actual TY-2020	Year over Year (YoY) Change %	Actual TY-2021	YoY Change %	Actual TY-2022	YoY Change %	Guide TY-2023	YoY Change % (Mid-Point)
Connected Devices, Software Licenses, & Other[1]	Non Recurring	Product	$560	-2%	$739	32%	$828	12%	$740-$760	-17%
Consumables	Recurring	Product	$76	-12%	$73	-3%	$75	3%		
Technical Services	Recurring	Service	$202	4%	$207	2%	$207	0%	$210-$220	4%
Advanced Services[2]	Recurring	Service	$54	24%	$113	109%	$186	65%	$200-$210	10%
Total Revenue			**$892**	**-1%**	**$1,132**	**27%**	**$1,296**	**14%**	**$1,150-$1,190**	**-10%**
Advanced Services % of Total Revenue			**6%**		**10%**		**14%**			**18%**
Recurring % of Total Revenue			**37%**		**35%**		**36%**			

1. Connected Devices, Software Licenses, and other include, but are not limited to, XT Series automated dispensing systems and products related to Central Pharmacy Dispensing Service and IV Compounding Service.
2. Includes Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth solutions, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software solutions.

© 2023 Omnicell, Inc.

Financial Snapshot

Q1-2023	Results	YoY Change %
Total Revenues	$291 Million	-9%
Non-GAAP Gross Margin %	44.8%	-410bps
Non-GAAP Operating Expenses	$117 Million	-2%
Non-GAAP EBITDA	$27 Million	-47%
Non-GAAP Diluted Earnings Per Share	$0.39	-53%

See Appendix for a reconciliation of Q1-2023 Non-GAAP Gross Margin, Q1-2023 Non-GAAP Operating Expenses, Q1-2023 Non-GAAP EBITDA and Q1-2023 Non-GAAP Diluted Earnings Per Share to their most directly comparable GAAP financial measures.

© 2023 Omnicell, Inc.

2023 Financial Guidance

	Q2-2023	TY-2023
Bookings[1]	Not Provided	$1.000-$1.100 Billion
Total Revenues	$278-$288 Million	$1.150-$1.190 Billion
Product Revenues	$181-$186 Million	$740-$760 Million
Service Revenues	$97-$102 Million	$410-$430 Million
Technical Services Revenues	Not Provided	$210-$220 Million
Advanced Services Revenues	Not Provided	$200-$210 Million
Non-GAAP EBITDA	$22-$28 Million	$120-$135 Million
Non-GAAP EPS	$0.25-$0.35	$1.55-$1.80

We do not provide a reconciliation of forward-looking non-GAAP guidance to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort.

1. We define bookings generally as: (i) the value of non-cancelable contracts for our connected devices, software products, and Advanced Services (although, for those Advanced Services contracts without a minimum commitment, bookings only includes the amount of revenue that has been recognized once the services have been provided); and (ii) for our consumables, the value of orders placed through our Omnicell Storefront online platform or through written or telephonic orders. We typically exclude technical services and other less significant items ancillary to our products and services, such as freight revenue from bookings.
2. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spain, Kingdom of Saudi Arabia and Australia/New Zealand.

Long-Term Value Creation Opportunities

Leadership position in the digital transformation of healthcare with $90 Billion+ TAM[2]

Emerging and scaling of Advanced Services offerings

Platform adoption, expansion, market share gains, and upgrade cycles supporting growth

Strong balance sheet should enable transformation to new business model with expected higher gross margins, EBITDA, and free cash flows

© 2023 Omnicell, Inc.

A Better Way: Our Environment, Social, Governance, and Innovation Strategy



Environment

Innovating for Energy Efficiency

Actively contribute to realize 1.5° Celsius future by 2030



Governance

Doing the Right Thing

Identify, prevent, and mitigate risk to Omnicell to create, preserve, and realize value



Social

Every Voice Counts

Create a culture of inclusivity, engagement, and well-being to be an employer of choice



Innovation

Accelerating for Perfection

Design and deliver our products to minimize our environmental footprint while maximizing patient outcomes

© 2023 Omnicell, Inc.

A Better Way: Our Approach to ESG



Our Approach

- Omnicell uses a risk-based approach designed to strategically align our ESG goals and targets to address the risks we believe are most material to our organization
- In 2021, Omnicell identified 11 material topic areas that our internal and external stakeholders indicated are strategic or paramount to our business, and developed strategic goals and targets in response
- In 2022, we executed on strategic short-term actions and honed our strategy, making marked progress towards our targets and long-term goals
- Looking forward, we plan to continue reviewing these material topic areas to reflect the changing business and ESG&I landscape

Significance of Our Approach

- **Create a Competitive Advantage:** We believe our robust ESG program is a credible, authentic "differentiator" from our competition
- **Prepare Omnicell for Upcoming Regulation:** As the regulatory landscape shifts toward mandatory reporting and disclosure, measuring ESG progress should help prepare Omnicell to be compliant with future requirements
- **Enhance Resiliency with Relevant Goals & Targets:** Year over year improvement towards our strategically-aligned public goals and targets is expected to increase Omnicell's adaptability and resilience

© 2023 Omnicell, Inc.

A Better Way: ESG in Action

Environment

- Decreased Scope 1 and 2 emissions in 2022 by 17% from 2021
- Conducted a Climate Risk Assessment to identify top risks to domestic operations and sites
- Implemented reusable foam inserts for XT cabinet drawer service shipments, reducing our foam packaging waste for single-deep drawers by 76% in 2022

Social

- Finalized creation of four Employee Resource Groups and established a Global Culture Committee
- Launched a charitable efforts platform, corporate matching program for employee donations, and paid Volunteer Time Off program intended to maximize social impact
- Introduced new talent development programs and enhanced performance reviews and employee feedback mechanisms

Governance

- Recent Board refreshment with 2 new Directors added in last 3 years
- Regularly evaluate Board composition
- Lead Independent Director with clear responsibilities
- Advancing our information security zero trust journey

Innovation

- Working to formalize a charitable product donation program by 2024
- Earned a 2022 Retail Excellence (REX) Award in the Technology and Automation category for EnlivenHealth from Drug Store News
- Exploring opportunities to incorporate innovative processes and materials – such as recycled materials – and reducing material waste in our product design

2022 ESG Report

Published third annual ESG Report in April 2023

89%

of Board is independent

44%

of Board are women or racially or ethnically diverse



© 2023 Omnicell, Inc. THE USE BY OMNICELL, INC. OF ANY MSCI ESG RESEARCH LLC OR ITS AFFILIATES ("MSCI") DATA, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT, RECOMMENDATION, OR PROMOTION OF OMNICELL, INC. BY MSCI. MSCI SERVICES AND DATA ARE THE PROPERTY OF MSCI OR ITS INFORMATION PROVIDERS AND ARE PROVIDED 'AS-IS' AND WITHOUT WARRANTY. MSCI NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI.

We Expect that Omnicell is Positioned to Win Based on Our Belief that:

Omnicell has the **right solutions and the right business model** to solve the medication management problem that the healthcare system is facing

Omnicell is positioned as the leading strategic partner to health systems in large and growing market segments with **$90 Billion+ TAM**[1]

Omnicell is scaling Advanced Services to capitalize on the many growth opportunities ahead — with Advanced Services growth continuing to **drive recurring revenue growth**

With a track record of strong financial performance and disciplined execution, Omnicell is **poised to drive profitable growth**

Executing on our vision to deliver the most compelling automation and services that accelerate pharmacy perfection

© 2023 Omnicell, Inc.

1. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spain, Kingdom of Saudi Arabia and Australia/New Zealand..

Appendix

Omnicell, Inc.

Reconciliation of GAAP to Non-GAAP

(Unaudited, in thousands, except per share data and percentage)

	Three Months Ended March 31,	
	2023	**2022**
Reconciliation of GAAP revenues to non-GAAP revenues:		
GAAP revenues	$ 290,629	$ 318,828
Acquisition accounting impact related to deferred revenues	—	378
Non-GAAP revenues	$ 290,629	$ 319,206
Reconciliation of GAAP gross profit to non-GAAP gross profit:		
GAAP gross profit	$ 125,029	$ 150,047
GAAP gross margin	*43.0%*	*47.1%*
Share-based compensation expense	2,008	2,244
Amortization of acquired intangibles	3,025	3,314
Acquisition accounting impact related to deferred revenues	—	378
Severance-related expenses	144	156
Non-GAAP gross profit	$ 130,206	$ 156,139
Non-GAAP gross margin	*44.8%*	*48.9%*
Reconciliation of GAAP operating expenses to non-GAAP operating expenses:		
GAAP operating expenses	$ 147,992	$ 144,963
GAAP operating expenses % to total revenues	*50.9%*	*45.5%*
Share-based compensation expense	(12,034)	(13,964)
Amortization of acquired intangibles	(5,217)	(5,739)
Acquisition-related expenses	(246)	(1,395)
Impairment and abandonment of operating lease right-of-use and other assets related to facilities [(a)]	(8,420)	(1,753)
Severance-related expenses	(5,170)	(3,371)
Non-GAAP operating expenses	$ 116,905	$ 118,741
Non-GAAP operating expenses as a % of total non-GAAP revenues	*40.2%*	*37.2%*

[(a)] For the three months ended March 31, 2023, impairment charges of other assets were approximately $0.6 million related to property and equipment in connection with restructuring activities for optimization of certain leased facilities.

© 2023 Omnicell, Inc.

Omnicell, Inc.

Reconciliation of GAAP to Non-GAAP

(Unaudited, in thousands, except per share data and percentage)

	Three Months Ended March 31,	
	2023	**2022**
Reconciliation of GAAP income (loss) from operations to non-GAAP income from operations:		
GAAP income (loss) from operations	$ (22,963)	$ 5,084
GAAP operating income (loss) % to total revenues	*(7.9)%*	*1.6%*
Share-based compensation expense	14,042	16,208
Amortization of acquired intangibles	8,242	9,053
Acquisition accounting impact related to deferred revenues	—	378
Acquisition-related expenses	246	1,395
Impairment and abandonment of operating lease right-of-use and other assets related to facilities [(a)]	8,420	1,753
Severance-related expenses	5,314	3,527
Non-GAAP income from operations	$ 13,301	$ 37,398
Non-GAAP operating margin (non-GAAP operating income as a % of total non-GAAP revenues)	*4.6%*	*11.7%*
Reconciliation of GAAP net income (loss) to non-GAAP net income:		
GAAP net income (loss)	$ (15,000)	$ 8,213
Share-based compensation expense	14,042	16,208
Amortization of acquired intangibles	8,242	9,053
Acquisition accounting impact related to deferred revenues	—	378
Acquisition-related expenses	246	1,395
Impairment and abandonment of operating lease right-of-use and other assets related to facilities [(a)]	8,420	1,753
Severance-related expenses	5,314	3,527
Amortization of debt issuance costs	1,045	1,038
Tax effect of the adjustments above [(b)]	(4,886)	(3,601)
Non-GAAP net income	$ 17,423	$ 37,964

[(a)] For the three months ended March 31, 2023, impairment charges of other assets were approximately $0.6 million related to property and equipment in connection with restructuring activities for optimization of certain leased facilities.

[(b)] Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2023 and 2022.

© 2023 Omnicell, Inc.

Omnicell, Inc.
Reconciliation of GAAP to Non-GAAP
(Unaudited, in thousands, except per share data and percentage)

	Three Months Ended March 31,	
	2023	2022
Reconciliation of GAAP net income (loss) per share - diluted to non-GAAP net income per share - diluted:		
Shares - diluted GAAP	44,887	47,918
Shares - diluted non-GAAP [c]	45,120	46,000
GAAP net income (loss) per share - diluted	$ (0.33)	$ 0.17
Share-based compensation expense	0.31	0.35
Amortization of acquired intangibles	0.18	0.20
Acquisition accounting impact related to deferred revenues	—	0.01
Acquisition-related expenses	0.01	0.03
Impairment and abandonment of operating lease right-of-use and other assets related to facilities	0.19	0.04
Severance-related expenses	0.12	0.08
Amortization of debt issuance costs	0.02	0.02
Non-GAAP dilutive shares impact from convertible note hedge transaction [c]	—	0.01
Tax effect of the adjustments above [b]	(0.11)	(0.08)
Non-GAAP net income per share - diluted	$ 0.39	$ 0.83
Reconciliation of GAAP net income (loss) to non-GAAP EBITDA[d]:		
GAAP net income (loss)	$ (15,000)	$ 8,213
Share-based compensation expense	14,042	16,208
Interest (income) and expense, net	(3,074)	(33)
Depreciation and amortization expense	21,974	21,124
Acquisition accounting impact related to deferred revenues	—	378
Acquisition-related expenses	246	1,395
Impairment and abandonment of operating lease right-of-use and other assets related to facilities [a]	8,420	1,753
Severance-related expenses	5,314	3,527
Amortization of debt issuance costs	1,045	1,038
Benefit from income taxes	(6,182)	(3,243)
Non-GAAP EBITDA	$ 26,785	$ 50,360
Non-GAAP EBITDA margin (non-GAAP EBITDA as a % of total non-GAAP revenues)	*9.2%*	*15.8%*

[a] For the three months ended March 31, 2023, impairment charges of other assets were approximately $0.6 million related to property and equipment in connection with restructuring activities for optimization of certain leased facilities.

[b] Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2023 and 2022.

[c] For the three months ended March 31, 2022, non-GAAP diluted shares excluded approximately 1.9 million shares related to the impact of dilutive convertible senior notes for which the Company is economically hedged through its anti-dilutive convertible note hedge transaction.

[d] Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments.

© 2023 Omnicell, Inc.

Omnicell, Inc.

Reconciliation of GAAP to Non-GAAP

(Unaudited, in thousands, except per share data and percentage)

	Three Months Ended March 31, 2023	Three Months Ended December 31, 2022	Three Months Ended September 30, 2022	Three Months Ended June 30, 2022	Year Ended December 31, 2017
Reconciliation of GAAP net income (loss) to non-GAAP EBITDA [a]:					
GAAP net income (loss)	$ (15,000)	$ (28,408)	$ 16,774	$ 9,069	$ 30,518
Share-based compensation expense	14,042	17,516	17,310	17,213	21,857
Interest (income) and expense, net	(3,074)	(2,410)	(1,136)	(142)	6,072
Depreciation and amortization expense	21,974	22,088	21,826	21,893	51,511
Acquisition accounting impact related to deferred revenues	-	40	183	302	1,252
Acquisition-related expenses	246	246	251	263	1,715
Impairment and abandonment of operating lease right-of-use and other assets related to facilities	8,420	3,992	297	3,340	-
Ransomware-related expenses, net of insurance recoveries	-	73	1,027	1,374	-
Severance-related and other expenses	5,314	18,782	2,494	-	4,752
Amortization of debt issuance costs	1,045	1,043	1,042	1,041	-
Provision for (benefit from) income taxes	(6,182)	(7,106)	543	1,705	(26,006)
Non-GAAP EBITDA	$ 26,785	$ 25,856	$ 60,611	$ 56,058	$ 91,671

[a] Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments.

© 2023 Omnicell, Inc.

Omnicell, Inc.
Reconciliation of GAAP to Non-GAAP
(Unaudited, in thousands, except per share data and percentage)

	Quarter Ended March 31, 2023
Convertible senior notes, net	$ 567,342
Cash and cash equivalents	(340,413)
Net debt	$ 226,929
Net debt/Non-GAAP EBITDA [a]	1.3

	Quarter Ended March 31, 2023
Revolver availability	$ 500,000
Cash and cash equivalents	340,413
Liquidity	$ 840,413

	Year Ended December 31, 2017
Long-term debt, current portion, net	$ 15,208
Long-term debt, net	194,917
Total debt, net	$ 210,125
Cash and cash equivalents	(32,424)
Net debt	$ 177,701
Net debt/Non-GAAP EBITDA [a]	1.9

	Year Ended December 31, 2017
Revolver availability	$ 280,500
Cash and cash equivalents	32,424
Liquidity	$ 312,924

[a] Net Debt / EBITDA = (Total Debt - Cash and Cash Equivalents) / Trailing Twelve Months Non-GAAP EBITDA

© 2023 Omnicell, Inc.


Omnicell®